Feature | TCT | November 09, 2017

TCT 2017 Late-breaking Clinical Trial Presentations

TCT 2017 late-breaking trials and studies that will be presented on the latest cardiology technology clinical trials.

November 9, 2017 — From numerous high-quality submissions, Transcatheter Cardiovascular Therapeutics (TCT) has selected 12 late-breaking clinical trials and 16 first report Investigations that are guaranteed to impact patient care and future directions in cardiovascular technologies. 

 

Monday, October 30 - Main Arena I

Late-Breaking Clinical Trials 1

CULPRIT-SHOCK: A Randomized Trial of Multivessel PCI in Cardiogenic Shock. Presenter is Holger Thiele.

EXCEL QOL: Quality of Life After PCI vs. CABG in Left Main Coronary Artery Disease. Presenter is Suzanne J. Baron.

DKCRUSH-V: A Randomized Trial of Double Kissing Crush vs. Provisional Stenting for Treatment of Distal Left Main Bifurcation Lesions. Presenter is Shao-Liang Chen.

 

 

First Report Investigations 1

HREVS: A Randomized Trial of PCI vs. CABG vs Hybrid Revascularization in Patients With Coronary Artery Disease. Presenter is Vladimir Ganyukov.

HARMONEE: A Randomized Trial of a Bioabsorbable Polymer-Based DES With a Luminal CD34+ Antibody Coating vs. a Durable Polymer-Based DES in Patients With Coronary Artery Disease. Presenter is Shigeru Saito.

DARE: A Randomized Trial of a Drug-Eluting Balloon vs. a Metallic DES in Patients With Coronary Artery In-Stent Restenosis. Presenter is Jose P.S. Henriques.

VAMPIRE 3: A Randomized Trial of Distal Filter Protection During PCI of High-Risk Plaque. Presenter is Kiyoshi Hibi. 

 

 

Tuesday, October 31, 2017 - Main Arena II

Late-Breaking Clinical Trials 2: Co-sponsored by the Lancet

ABSORB IV: 30-Day Outcomes From a Randomized Trial of a Bioresorbable Scaffold vs. a Metallic DES in Patients With Coronary Artery Disease. Presented by Gregg W. Stone.

ABSORB III: 3-Year Outcomes From a Randomized Trial of a Bioresorbable Scaffold vs a Metallic DES in Patients With Coronary Artery Disease. Presented by Stephen G. Ellis.

PARTNER 2A and SAPIEN 3 Cost-effectiveness: Cost-effectiveness of TAVR vs SAVR in Intermediate-Risk Patients With Aortic Stenosis. Presented by David J. Cohen.

 

 

 

First Report Investigations 2

ABSORB II: 4-Year Outcomes From a Randomized Trial of a Bioresorbable Scaffold vs a Metallic DES in Patients With Coronary Artery Disease. Presented by Bernard R. Chevalier.

CrossBoss First: A Randomized Trial of Antegrade Dissection and Re-entry vs Standard Wire Escalation for Crossing Coronary Artery Chronic Total Occlusions. Presented by Emmanouil S. Brilakis.

REVASC: A Randomized Trial to Assess Recovery of Left Ventricular Function After PCI of Coronary Artery Chronic Total Occlusions. Presented by Kambis Mashayekhi.

FAVOR II China: Diagnostic Accuracy of the Angiographic Quantitative Flow Ratio (QFR) FFR-Angiography in Patients With Coronary Artery Disease. Presented by Bo Xu.

FAVOR II Europe Japan: Diagnostic Accuracy of the Angiographic Quantitative Flow Ratio (QFR) FFR-Angiography in Patients With Coronary Artery Disease. Presented by Jelmer Westra.

 

 

Wednesday, November 1, 2017 - Main Arena III

Late-Breaking Clinical Trial 3: Co-sponsored by the Journal of the American Medical Association

SENIOR: A Randomized Trial of a Bioabsorbable Polymer-Based Metallic DES vs. a BMS With Short DAPT in Patients With Coronary Artery Disease Older Than 75 Years. Presented by Olivier Varenne.

DAPT STEMI: A Randomized Trial of 6-Month vs. 12-Month DAPT After DES Implantation in STEMI. Presented by Elvin Kedhi.

REDUCE: A Randomized Trial of 3-Month vs 12-Month DAPT After Implantation of a Bioabsorbable Polymer-Based Metallic DES With a Luminal CD34+ Antibody Coating in Patients With ACS. Presented by Harry Suryapranata.

 

 

First Report Investigations 3

MITRAL: 30-Day Outcomes of Transcatheter MV Replacement in Patients With Severe Mitral Valve Disease Secondary to Mitral Annular Calcification or Failed Annuloplasty Rings. Presented by Mayra Guerrero.

INTREPID: 30-Day Outcomes of Transcatheter MV Replacement in Patients With Severe Mitral Regurgitation. Presented by Paul Sorajja.

TENDYNE: 1-Year Outcomes of Transcatheter MV Replacement in Patients With Severe Mitral Regurgitation. Presented by David W.M. Muller.

TRACER: 6-Month Outcomes of Transcatheter MV Neochordal Repair with the Harpoon System in Patients With Severe Primary Mitral Regurgitation. Presented by James S. Gammie.

MAVERIC: 6-Month Outcomes of Transcatheter MV Repair in Patients With Severe Secondary Mitral Regurgitation. Presented by Stephen G. Worthley.

 

 

Thursday, November 2, 2017 - Main Arena IV

Late-Breaking Clinical Trials 4

PREVAIL: 5-Year Outcomes From a Randomized Trial of Left Atrial Appendage Closure (LAA) vs. Medical Therapy in Patients With Non-Valvular Atrial Fibrillation. Presented by Vivek Y. Reddy.

ORBITA: A Randomized, Sham-Controlled Trial of PCI in Patients With Coronary Artery Disease. Presented by Rasha Al-Lamee.

FAME 2: 3-Year Clinical and Cost-Effectiveness Outcomes of FFR-Guided PCI in Patients With Coronary Artery Disease. Presented by William F. Fearon.

 

 

First Report Investigations 4

TRI-REPAIR: 30-Day Outcomes of Transcatheter TV Repair in Patients With Severe Secondary Tricuspid Regurgitation. Presented by Georg Nickenig.

FORMA: 30-Day Outcomes of Transcatheter TV Repair in Patients With Severe Secondary Tricuspid Regurgitation. Presented by Susheel K. Kodali.

 

 

Other Studies, Videos and Articles From TCT 2017

VIDEO: What Went Wrong With the Absorb Stent? – discussion on the Absorb trials at TCT 2017 with Ajay Kirtane, M.D.

Current State of Bioresorbable Stent Technology

Positive, Sustained Improvements Seen at One Year in SCOUT I With Transcatheter Tricuspid Repair

VIDEO: Transcatheter Mitral Valve Implantation in Practice and Technologies in Development

VIDEO: The Role and Responsibilities of the Cath Lab Manager

VIDEO: New Frontiers in Radial Access

VIDEO: TAVR For Asymptomatic Severe Aortic Stenosis – with Philippe Genereux, M.D.

SURTAVI and FORWARD Studies Reinforce Hemodynamic Benefits of Evolut TAVR Platform in Intermediate-Risk Patients

VIDEO: Overview of the National Cardiogenic Shock Initiative — with William W. O’Neill, M.D.

Supersaturated Oxygen Therapy Reduces Infarct Size for High-Risk Stented AMI Patients

VIDEO: How Transcatheter PFO Closure Can Reduce Cryptogenic Stroke — with John Rhodes, M.D.

VIDEO: Update of Mitral Valve Repair and Replacement Technologies — with Ted Feldman, M.D.

4C Medical's Novel Transcatheter Mitral Valve Presented at TCT 2017 Shark Tank Innovation Competition

VIDEO: Cath Lab of the Future Cardiovascular Technologies to Watch — with Juan Granada, M.D.

VIDEO: Converting to Bundled Payments for PCI — with Peter Duffy, M.D.

 

For more information: www.crf.org/tct/agenda/2017-late-breaking-trials-and-first-report-investigations

 

 

Links to Late-breaking Trials at Other Meetings: 

SCAI 2017 Late-Breaking Clinical Trial Presentations

Heart Rhythm Society 2017 Late-Breaking Electrophysiology Trials

ACC 2017 Late-Breaking Trials

TCT 2016 Late-breaking Trials and First Reports

Related Content

Nuance Communications Inc. introduced Nuance Cardiovascular CAPD, a new computer-assisted physician documentation (CAPD) solution designed to help cardiologists improve the quality of complex documentation and the accuracy of reimbursement for cardiac catheterization procedures. The Nuance Cardiovascular CAPD solution is available through a partnership with ZHealth for this solution, which is based on patented algorithms built with ZHealth’s interventional documentation and coding expertise.
News | Cath Lab | January 31, 2020
January 29, 2020 – Nuance Communications Inc.
Videos | Cath Lab | January 09, 2020
Haval Chweich, M.D., medical director of the cardiac critical care unit (CCU) at Tufts Medical Center, and assistant...
People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.  In early December 2019, leaders of the European Association for Cardiothoracic Surgery (EACTS) withdrew their support for European practice guidelines that endorse the use of coronary stents in many patients with left main coronary artery disease.

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.

News | Cath Lab | January 02, 2020 | Dave Fornell, Editor
January 2, 2020 — In early December 2019, leaders of the European As...
News | Cath Lab | December 18, 2019
December 18, 2019 — Cook Medical initiated a recall of its CrossCath Support Catheters in November, which the U.S.
Gallery | Cath Lab | October 31, 2019 | Dave Fornell, Editor
This is a photo essay of the interventional cardiology and structural heart technologies on the expo floor and discus
The Alphenix Aero Package from Canon Medical Systems USA, Inc. enables OBLs and ASCs to attain premium technology at a flexible price point by tailoring Canon Medical’s Alphenix systems to fit their facilities’ needs.

The Alphenix Aero Package from Canon Medical Systems USA, Inc. enables OBLs and ASCs to attain premium technology at a flexible price point by tailoring Canon Medical’s Alphenix systems to fit their facilities’ needs.

Technology | Cath Lab | October 28, 2019
Office based labs (OBLs) and ambulatory surgery centers (ASCs) require a fresh perspective from imaging vendors.
Marco Costa, M.D., Ph.D., MBA, president, UH Harrington Heart and Vascular Institute, performing a cath lab procedure.

Marco Costa, M.D., Ph.D., MBA, president, UH Harrington Heart and Vascular Institute, performing a cath lab procedure.

News | Cath Lab | October 28, 2019
October 28, 2019 — Leaders within University Hospitals and the Harrington Heart and Vascular Institute had a vision t
OmniVision Announces Guinness World Record for Smallest Image Sensor

OmniVision's OVM6948 CameraCubeChip, a fully packaged, wafer-level camera module measuring 0.65mm x 0.65mm x 1.158mm, built on OmniVision's OV6948, winner of the Guinness World Record for “The Smallest Image Sensor Commercially Available.”

News | Cath Lab | October 22, 2019
October 22, 2019 — OmniVision Technologies Inc.
People watch the presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., live in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long term surgical outcomes. #TCT2019

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes. 

Feature | Cath Lab | October 03, 2019
October 3, 2019 – Five-year data from the EXCEL Trial showed patients with left main coronary disease treated with pe
Overlay Init